Regeneron Reports New Data on COVID-19 Therapy
The investigational antibody used to treat President Trump shows it reduced viral load and medical visits.
The investigational antibody used to treat President Trump shows it reduced viral load and medical visits.
A study conducted in China aimed to assess factors such as viral load rebound (VLR), reduction in cycle threshold values, time until VLR, and symptom…
Phase 2 study of healthcare workers’ safety in high-risk populations.
There is value in leveraging the contributions of nurses, laboratorians, and informaticists in antimicrobial stewardship.
Latest discoveries around HpaA’s implications for immune response and disease progression.
The assay, the cobas Malaria test, is manufactured by Roche, and will be available in the United States at the end of Q2 2024.
The long-term benefits of antimicrobial use and resistance (AUR) reporting is about improving patient care and combating resistance.
Insights on Sofosbuvir levels in pregnant women.
A new strategy for universal infant immunization in the 2023-2024 RSV season faces implementation and medication access barriers.
Here is a review of an opportunistic treatment approach to HCV infection in this patient population in a European study and some of the potential…
The evolution of treatment for hepatitis C virus during the past 15 years has been astounding, and we now are able to talk about how…